On May 17, the U.S. Food & Drug Administration ("FDA") issued two important draft guidance documents, which clarify the agency's approach to requirements and incentives in the realm of pediatric drug development.
On May 17, the U.S. Food & Drug Administration (“FDA”) issued two important draft guidance documents, which clarify the agency’s approach to requirements and incentives in the realm of.
FDA issued two new guidances on development and clinical trials of pediatric medications replacing 2005 rules. Pediatric drugs are developed slower difficulty clinical testing. Adult drugs can be used off label for children. New rules incentivize pediatric drug development.
Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to planAbivax reports promising Phase 2b maintenance results